VectivBio Holding AG logo

VECT

VectivBio Holding AG

$5.42

Key Ratios

Key ratios of the VectivBio Holding AG post its Q4 2021 earnings

Return on Assets (ROA)
-0.6
Return on Equity (ROE)
-2.89
Dividend Per Share (DPS)
0

Highlights

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. VectivBio Holding AG’s return on assets (ROA) stands at -0.6.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. VectivBio Holding AG’s return on equity (ROE) stands at -2.89.

Dividend Per Share (DPS):

VectivBio Holding AG declared 0 dividend per share during the earnings announcement for Q4 2021.

Company Information

VectivBio is a global, clinical-stage biotechnology company focused on the discovery, development and commercialization of innovative treatments for severe rare conditions with high unmet medical need. The company is committed to pursuing product candidates with a clear mechanism of action and the potential to meaningfully transform and improve the lives of patients and their families. VectivBio’s product candidate, apraglutide, is a next-generation GLP-2 analog being developed as a differentiated therapeutic for a range of rare gastrointestinal (GI) diseases. Apraglutide is currently being evaluated in a global phase 3 clinical trial as a once-weekly treatment for short bowel syndrome with intestinal failure (SBS-IF).

Organisation
VectivBio Holding AG